Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Alimta — ALIMTA
Application NDA021462 (NDA)
Alimta — PEMETREXED
Application NDA208419 (NDA)
Alimta — PEMFEXY
Application NDA209472 (NDA)
Alimta — PEMETREXED DISODIUM
Application NDA214408 (NDA)
Alimta — PEMETREXED DISODIUM
Application NDA214218 (NDA)
Alimta — PEMETREXED DISODIUM
Application NDA214657 (NDA)
Alimta — PEMETREXED
Application NDA215179 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)